Business Wire | Jan 12, 2022 10:16AM EST

CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Jan. 12, 2022

ACTON, Mass.--(BUSINESS WIRE)--Jan. 12, 2022--Headline of release should read: Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 (instead of Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021).

The updated release reads:

INSULET TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS ON FEBRUARY 23, 2022

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod(r) brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2021 on February 23, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com/events, "Events and Presentations," and will be archived for future replay. To participate in the live call via phone, please pre-register online here to receive a telephone number, passcode, and a unique registrant ID required to enter the call.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005017/en/

CONTACT: Investor Relations: Deborah R. Gordon Vice President, Investor Relations (978) 600-7717 dgordon@insulet.com

CONTACT: Merrill Robichaud Investor Relations Coordinator (978) 932-0444 mrobichaud@insulet.com

CONTACT: Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 awiczek@insulet.com